文献速递乳腺MR

新辅助化疗期间多参数MRI的纵向变化可早期预测HER2阳性乳腺癌的治疗反应

The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer.
PubMed 文献 · Eur J Radiol · 2024-07-31

本研究纳入三个中心共164例HER2阳性乳腺癌患者,在基线和两个周期新辅助化疗后行多参数MRI,评估肿瘤最大径变化、ADC值变化和TIC变化。联合模型在训练集(AUC=0.87)、内部验证集(AUC=0.78)和外部验证集(AUC=0.79)的预测效能均优于临床病理模型。多参数MRI变化可预测HER2阳性乳腺癌早期治疗反应,可能有助于个体化治疗规划。

要点

  • 新辅助化疗两个周期后肿瘤最大径、ADC值变化和TIC变化是pCR的独立预测指标。
  • 联合模型在训练集、内部验证集和外部验证集的AUC分别为0.87、0.78和0.79。
  • 联合模型在各数据集中的预测效能均优于临床病理模型。

核心结论

  • 多参数MRI的纵向变化可预测HER2阳性乳腺癌的早期治疗反应,可能有助于个体化治疗规划。

研究设计与样本

  • 多中心研究,共纳入三个中心164例HER2阳性乳腺癌患者,分为训练集95例、内部验证集31例和独立外部验证集38例;在基线和两个周期新辅助化疗后行多参数MRI,评估最大径变化、ADC值变化和TIC变化,采用单因素和多因素logistic回归筛选pCR独立预测指标并建立临床病理模型和联合模型。

诊断标准与关键数值

  • 早期新辅助化疗后最大径(OR=0.913,95%CI=0.953-0.994,p=0.026)、ADC值变化(OR=1.005,95%CI=1.005-1.008,p=0.007)和TIC变化(OR=3.974,95%CI=1.276-12.358,p=0.017)被确定为新辅助化疗反应的最佳预测指标;联合模型训练集AUC=0.87、内部验证集AUC=0.78、外部验证集AUC=0.79。

临床应用与阅片要点

  • 作者认为多参数MRI变化可预测HER2阳性乳腺癌早期治疗反应,可能有助于个体化治疗规划。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate whether longitudinal changes in multiparametric MRI can predict early response to neoadjuvant chemotherapy (NAC) for HER2-positive breast cancer (BC) and to further establish quantitative models based on these features.

METHODS: A total of 164 HER2-positive BC patients from three centers were included. MRI was performed at baseline and after two cycles of NAC (early post-NAC). Clinicopathological characteristics were enrolled. MRI features were evaluated at baseline and early post-NAC, as well as longitudinal changes in multiparametric MRI, including changes in the largest diameter (LD) of the tumor (ΔLD), apparent diffusion coefficient (ADC) values (ΔADC), and time-signal intensity curve (TIC) (ΔTIC). The patients were divided into a training set (n = 95), an internal validation set (n = 31), and an independent external validation set (n = 38). Univariate and multivariate logistic regression analyses were used to identify the independent indicators of pCR, which were then used to establish the clinicopathologic model and combined model. The AUC was used to evaluate the predictive power of the different models and calibration curves were used to evaluate the consistency of the prediction of pCR in different models. Additionally, decision curve analysis (DCA) was employed to determine the clinical usefulness of the different models.

RESULTS: Two models were enrolled in this study, including the clinicopathologic model and the combined model. The LD at early post-NAC (OR=0.913, 95 % CI=0.953-0.994 p = 0.026), ΔADC (OR=1.005, 95 % CI=1.005-1.008, p = 0.007), and ΔTIC (OR=3.974, 95 % CI=1.276-12.358, p = 0.017) were identified as the best predictors of NAC response. The combined model constructed by the combination of LD at early post-NAC, ΔADC, and ΔTIC showed good predictive performance in the training set (AUC=0.87), internal validation set (AUC=0.78), and external validation set (AUC=0.79), which performed better than the clinicopathologic model in all sets.

CONCLUSIONS: The changes in multiparametric MRI can predict early treatment response for HER2-positive BC and may be helpful for individualized treatment planning.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Chen S, Zheng B, Tang W, et al. The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer. Eur J Radiol. 2024. PMID: 39098252. doi:10.1016/j.ejrad.2024.111656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。